Characterization and evaluation of the antitumour activity of a dual-targeting monoclonal antibody against claudin-3 and claudin-4

Anticancer Research

Volumn 30, Issue 11, 2010, Pages 4555-4562

  Kato Nakano, Mariko ^a   Suzuki, Masayo ^a   Kawamoto, Shinobu ^a   Furuya, Akiko ^a   Ohta, So ^a   Nakamura, Kazuyasu ^a   Ando, Hiroshi ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Antibody dependent cellular cytotoxicity; Cancer therapy; Claudin; Complement dependent cytotoxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CLAUDIN; CLAUDIN 3; CLAUDIN 4; CLAUDIN 5; CLAUDIN 6; CLAUDIN 9; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; KM 3907 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CHINESE HAMSTER; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG INHIBITION; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG TARGETING; FEMALE; FLOW CYTOMETRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BREAST NEOPLASMS; CELL LINE; CELL PROLIFERATION; CHO CELLS; CRICETINAE; CRICETULUS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FLOW CYTOMETRY; HUMANS; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED ICR; MICE, SCID; MOLECULAR SEQUENCE DATA; OVARIAN NEOPLASMS; SEQUENCE HOMOLOGY, AMINO ACID; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78650237473     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Satoh M, Iida S and Shitara K: Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opin Biol Ther 6: 1161-1173, 2006.
2. Kubota T, Niwa R, Satoh M, Akinaga S, Shitara K and Hanai N: Engineered therapeutic antibodies with improved effector functions. Cancer Sci 100: 1566-1572, 2009.
3. Tsukita S, Furuse M and Itoh M: Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2: 285-293, 2001.
4. Offner S, Hekele A, Teichmann U, Weinberger S, Gross S, Kufer P, Itin C, Baeuerle PA and Kohleisen B: Epithelial tight junction proteins as potential antibody targets for pancarcinoma therapy. Cancer Immunol Immunother 54: 431-445, 2005.
5. Katahira J, Sugiyama H, Inoue N, Horiguchi Y, Matsuda M and Sugimoto N: Clostridium perfringens enterotoxin utilizes two structurally related membrane proteins as functional receptors in vivo. J Biol Chem 272: 26652-26658, 1997.
6. Morin PJ: Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res 65: 9603-9606, 2005.
7. Kominsky SL: Claudins: emerging targets for cancer therapy. Expert Rev Mol Med 8: 1-11, 2006.
8. Resnick MB, Gavilanez M, Newton E, Konkin T, Bhattacharya B, Britt DE, Sabo E and Moss SF: Claudin expression in gastric adenocarcinomas: a tissue microarray study with prognostic correlation. Hum Pathol 36: 886-892, 2005.
9. Konecny GE, Agarwal R, Keeney GA, Winterhoff B, Jones MB, Mariani A, Riehle D, Neuper C, Dowdy SC, Wang HJ, Morin PJ and Podratz KC: Claudin-3 and claudin-4 expression in serous papillary, clear-cell, and endometrioid endometrial cancer. Gynecol Oncol 109: 263-269, 2008.
10. Choi YL, Kim J, Kwon MJ, Choi JS, Kim TJ, Bae DS, Koh SS, In YH, Park YW, Kim SH, Ahn G and Shin YK: Expression profile of tight junction protein claudin-3 and claudin-4 in ovarian serous adenocarcinoma with prognostic correlation. Histol Histopathol 22: 1185-1195, 2007.
11. Lanigan F, McKiernan E, Brennan DJ, Hegarty S, Millikan RC, McBryan J, Jirstrom K, Landberg G, Martin F, Duffy MJ and Gallagher WM: Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer. Int J Cancer 124: 2088-2097, 2009.
12. Kominsky SL, Tyler B, Sosnowski J, Brady K, Doucet M, Nell D, Smedley JG 3rd, McClane B, Brem H and Sukumar S: Clostridium perfringens enterotoxin as a novel-targeted therapeutic for brain metastasis. Cancer Res 67: 7977-7982, 2007.
13. Saeki R, Kondoh M, Kakutani H, Tsunoda SI, Mochizuki Y, Hamakubo T, Tsutsumi Y, Horiguchi Y and Yagi K: A novel tumor-targeted therapy using a claudin-4-targeting molecule. Mol Pharmacol 76: 918-926, 2009.
14. Suzuki M, Kato-Nakano M, Kawamoto S, Furuya A, Abe Y, Misaka H, Kimoto N, Nakamura K, Ohta S and Ando H: Therapeutic antitumor efficacy of monoclonal antibody against claudin-4 for pancreatic and ovarian cancers. Cancer Sci 100: 1623-1630, 2009.
15. Brufsky A: Trastuzumab-based therapy for patients with HER2-positive breast cancer: From Early Scientific Development to Foundation of Care. Am J Clin Oncol 33: 186-195, 2010.
16. Chames P and Baty D: Bispecific antibodies for cancer therapy. Curr Opin Drug Discov Devel 12: 276-283, 2009.
17. Nakamura K, Tanaka Y, Fujino I, Hirayama N, Shitara K and Hanai N: Dissection and optimization of immune effector functions of humanized anti-ganglioside GM2 monoclonal antibody. Mol Immunol 37: 1035-1046, 2000.
18. Fujita K, Katahira J, Horiguchi Y, Sonoda N, Furuse M and Tsukita S: Clostridium perfringens enterotoxin binds to the second extracellular loop of claudin-3, a tight junction integral membrane protein. FEBS Lett 476: 258-261, 2000.
19. Nichols LS, Ashfaq R and Iacobuzio-Donahue CA: Claudin-4 protein expression in primary and metastatic pancreatic cancer: support for use as a therapeutic target. Am J Clin Pathol 121: 226-230, 2004.
20. Rahner C, Mitic LL and Anderson JM: Heterogeneity in expression and subcellular localization of claudins 2, 3, 4, and 5 in the rat liver, pancreas, and gut. Gastroenterology 120: 411-422, 2001.